Key result
PhenoAge acceleration is linked to ~82% higher mortality per SD, outperforming vascular aging markers.
Why the study?
Does estimated pulse wave velocity (ePWV) acceleration or blood-based biological age acceleration (PhenoAge and KDM) provide incremental prognostic value for all-cause and cardiovascular mortality beyond chronological age and mean blood pressure in older US and Chinese adults?
Cohort (n=12,424)
Yes
Does estimated pulse wave velocity (ePWV) acceleration or blood-based biological age acceleration (PhenoAge and KDM) provide incremental prognostic value for all-cause and cardiovascular mortality beyond chronological age and mean blood pressure in older US and Chinese adults?
Age-residualized estimated pulse wave velocity (ePWV acceleration) is an algebraic re-expression of chronological age and mean blood pressure with no incremental prognostic value for mortality, whereas blood-based biological age indices (PhenoAge and KDM) provide significant, transportable prognostic discrimination beyond age and blood pressure.
Answers are grounded in this paper and cite their sources.
Challenges incremental value of ePWV beyond age and BP; supports blood-based biological age for mortality prediction but requires prospective validation.
Estimated pulse wave velocity (ePWV) is widely reported as a measure of vascular age, yet it is computed from chronological age and mean blood pressure (MBP); whether its age-residualized component, ePWV acceleration, carries information beyond those inputs has never been tested. Among 3972 National Health and Nutrition Examination Survey (NHANES) participants aged 60 or older (1034 deaths, 330 cardiovascular) we asked whether ePWV acceleration is a quantity distinct from its own inputs, and compared its prognostic value with blood-based biological age, based on PhenoAge and the Klemera-Doubal method (KDM), for all-cause and cardiovascular mortality, validating the comparison in two Chinese cohorts (CHARLS, n = 7892; CLHLS, n = 560). Within each risk branch of the estimating equation, ePWV acceleration was reproduced exactly from its own inputs (R2 approximately 1; residual standard deviation below 1 × 10⁻11 m/s) and correlated 0.990 with MBP, whereas the blood-based accelerations were uncorrelated with MBP. PhenoAge acceleration (hazard ratio per standard deviation 1.82, 95% confidence interval 1.68 to 1.97) and KDM acceleration (1.64, 1.53 to 1.76) predicted mortality, were well calibrated, retained incremental discrimination once spline age and MBP were modeled (change in Harrell C + 0.036 and + 0.032), and did so under machine-learning survival models and in both Chinese cohorts. ePWV acceleration added none (- 0.0001) and was not jointly estimable with MBP. Within the indices examined, blood-based biological age carried transportable prognostic information beyond chronological age and blood pressure, whereas age-residualized ePWV was an algebraic re-expression of its inputs.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in Vascular aging and mortality risk in older adults (n=12,424). Blood-based biological age acceleration (PhenoAge and Klemera-Doubal method [KDM]) vs. Estimated pulse wave velocity (ePWV) acceleration, chronological age, and mean blood pressure (MBP) was evaluated on All-cause and cardiovascular mortality (HR 1.82, 95% CI 1.68-1.97). PhenoAge acceleration predicted mortality and improved discrimination, whereas ePWV acceleration added no incremental value.
Synapse has enriched 10 related papers. Consider them for comparative context: